perplexity

You are a longevity research analyst preparing a report titled "The Immortality Update: Deep Research on the Most Important Discoveries and News in Longevity Sciences from the Past 7 Days." Today's theme is The Immortality Update, emphasizing functional life extension. Your task:

- Use any global source.
- Only research credible sources (peer-reviewed journals, reputable institutions, major medical conferences).
- Only report on items confirmed by multiple credible sources.
- Only include items from the last 7 days.
- May include any longevity science, not just drugs or supplements.

Structure:

1. Introduction – Theme overview and functional life emphasis.
2. Key Findings – Senolytics, cell therapies, gene editing, metabolic regulators.
3. Basic Research vs Clinical Trials – Show differences clearly.
4. Technological Tools – New biomarkers, AI screening, imaging.
5. Ethical & Practical Considerations – Access, safety, costs.
6. Future Directions – Likely next steps for human healthspan.

Now let me compile this comprehensive research into a structured report on longevity science discoveries from the past week.

The Immortality Update: Deep Research on the Most Important Discoveries and News in Longevity Sciences from the Past 7 Days

Introduction: Functional Life Extension Takes Center Stage

The past week in longevity science has delivered a constellation of groundbreaking discoveries that move beyond simply extending lifespan toward the more critical goal of functional life extension—adding years of health, vitality, and independence rather than merely prolonging biological existence. From November 18-25, 2025, researchers worldwide have published significant findings across multiple domains: cellular rejuvenation through blood stem cell manipulation, immune system restoration via mitochondrial enhancement, advances in gene editing for age-related diseases, and novel therapeutic pathways targeting the fundamental biology of aging[1] [2] [3] [4].

These developments arrive at a pivotal moment. As populations age globally, with the number of individuals aged 65 and older expected to double by 2050 to 1.6 billion[5], the imperative to extend healthspan—not just lifespan—has never been more urgent. This week's discoveries reflect a maturation of the longevity field, with multiple therapies advancing from preclinical models into human trials and the first FDA approvals signaling regulatory acceptance of aging as a treatable condition.

Key Findings: Breakthrough Discoveries Across Multiple Domains

Senolytics: From Promise to Clinical Application

The senolytic field has achieved critical milestones this week, with multiple studies confirming both safety and preliminary efficacy in human populations. Blood vessel senescent cells have emerged as a particularly important target for metabolic health interventions[6] [7].

Research published on November 20, 2025, demonstrated that senescent cells accumulating in blood vessels drive metabolic dysfunction in preclinical models. When mice were treated with the senolytic compound fisetin, they exhibited fewer senescent blood vessel cells and improved glucose tolerance—suggesting a direct mechanistic link between vascular cellular aging and whole-body metabolic health[6]. This finding provides crucial validation for targeting endothelial senescence as a therapeutic strategy.

Meanwhile, senolytics continue advancing in ophthalmological applications. At the American Academy of Ophthalmology 2025 meeting, researchers presented data on UBX-1325 (foselutoclax), a senolytic being evaluated for diabetic macular edema. While the compound did not meet its primary non-inferiority endpoint against aflibercept at Week 24 in the ASPIRE Phase 2b trial, the data revealed potential for multimodal regimens combining senolytics with standard anti-VEGF therapies[8].

Blood Stem Cell Rejuvenation: Reversing Hematopoietic Aging

Two parallel discoveries this week have identified novel pharmacological approaches to reverse blood stem cell aging, with profound implications for immune system function and whole-body health.

Rhosin-Mediated Rejuvenation

On November 24, 2025, researchers at IDIBELL-Bellvitge Biomedical Research Institute in Barcelona announced that the drug Rhosin can rejuvenate aging blood stem cells by inhibiting RhoA, a protein that becomes hyperactivated as hematopoietic stem cells (HSCs) age[1] [2]. The study, published in *Nature Aging*, demonstrated that RhoA activity increases in response to elevated nuclear envelope tension in aging HSCs. By dampening this activity with Rhosin, scientists successfully rejuvenated aged stem cells in both laboratory and animal models[4].

"Overall, our experiments show that Rhosin did rejuvenate blood stem cells, increased the regenerative capacity of the immune system and improved the production of blood cells once transplanted in the bone marrow," explained Dr. Eva Mejía-Ramírez, study co-author[9]. The rejuvenated cells produced more balanced blood cell populations and exhibited restored capacity to generate both lymphoid and myeloid lineages—reversing the age-associated skewing that contributes to immunosenescence.

Lysosomal Targeting Strategy

Complementing this work, researchers at Mount Sinai published findings on November 23, 2025, showing that targeting lysosomal hyperactivity can reset aged stem cells to a more youthful state[2] [3]. "By slowing down the lysosomes and reducing their acidity, stem cells became healthier and could make new balanced blood cells and new stem cells much more effectively," said Dr. Ghaffari, lead investigator[2]. This approach improved the cells' ability to regenerate blood and immune cells by addressing a fundamental aspect of cellular aging—the dysregulation of autophagy and lysosomal function.

Cell Therapies and Regenerative Medicine

Telomerase Activation in Pulmonary Fibrosis

A significant advance in telomere biology was reported on November 17, 2025, with researchers demonstrating that messenger RNA (mRNA) encoding telomerase reverse transcriptase (TERT) can significantly reduce cellular aging in pulmonary fibrosis[10] [11]. The study showed that TERT mRNA activated telomerase, lengthened telomeres, reduced aging biomarkers, and decreased inflammation markers in human lung tissue precision-cut lung slices from fibrosis patients[10].

"According to our results, TERT therapy is a promising approach to improving the health of lung cells and slowing down and perhaps even reversing the development of fibrosis," said Professor Christian Bär, principal investigator[10]. Packaged in lipid nanoparticles, the therapeutic RNA could eventually be delivered through inhalation, offering a non-invasive approach to addressing telomere dysfunction.

Immune System Rejuvenation via Urolithin A

On November 25, 2025, scientists revealed that urolithin A (UA)—a metabolite produced when gut bacteria break down polyphenols from foods like pomegranates—can rejuvenate aging immune systems by targeting T cell mitochondria[12]. The study, published in *Nature Aging*, showed that UA supplementation in middle-aged adults improved immune cell function and reduced inflammatory markers following a 4-week supplementation period[13].

The compound works by increasing the number of functional cytotoxic T lymphocytes (CTLs), whose gradual disappearance is a hallmark of immunosenescence. UA also enhanced mitophagy—the selective removal of damaged mitochondria—thereby reducing oxidative stress and inflammation[12]. This represents the first time a mitochondrial support supplement has demonstrated such comprehensive effects on immune aging in humans.

Gene Editing Advances

CRISPR Gene Therapy for Alzheimer's Risk

A University of Kentucky-led team published groundbreaking results on November 23, 2025, demonstrating successful gene editing in living mice that switched the APOE4 gene—associated with high Alzheimer's risk—to its protective counterpart, APOE2[14]. The study, published in *Nature Neuroscience*, found that mice receiving the gene edit exhibited fewer Alzheimer's-related brain changes including amyloid plaque buildup and inflammation, along with stronger performance on memory tests[14].

"This model allows us to test what happens when we go from risk to resilience. Remarkably, even switching the gene later in life improved multiple aspects of Alzheimer's pathology at once," said lead author Lesley Golden[14]. People who inherit the APOE4 variant from both parents are approximately 15 times more likely to develop Alzheimer's disease, while those with APOE2 are equally protected—making this genetic intervention particularly promising[14].

CRISPR in Vivo Editing Advances

The field witnessed additional gene editing milestones, including the presentation of data on November 21, 2025, showing durable, precise *in vivo* CRISPR editing across cardiometabolic programs[15]. Scribe Therapeutics demonstrated that STX-1150 silenced PCSK9 without DNA modification, sustaining LDL cholesterol reductions for over 515 days in preclinical models. STX-1200 inactivated the LPA gene with greater than 95% efficacy at sub-0.5 mg/kg doses, while STX-1400 achieved saturated APOC3 editing in primates, sharply lowering triglycerides[15].

Metabolic Regulators and Caloric Restriction Mimetics

GLP-1 Receptor Agonists as Longevity Drugs

A pivotal study published on November 23, 2025, in *Cell Metabolism* demonstrated that GLP-1 receptor agonism counteracts aging across multiple organs in a largely weight-neutral context[16]. Male mice treated with the GLP-1R agonist exenatide showed progressive increases in forelimb grip strength and motor performance over six months without meaningful changes in body weight[16].

The study revealed widespread counteraction of age-related transcript changes across the hypothalamus, frontal cortex, adipose tissue, heart, skeletal muscle, and circulating white blood cells. Epigenetic aging signals showed tissue-specific reversal, with DNA methylation patterns moving in an anti-aging direction across multiple organs[16]. Critically, the benefits required hypothalamic GLP-1 receptor signaling, indicating a brain-body axis coordinating systemic rejuvenation[16].

These findings support growing evidence that GLP-1s may represent "the first true longevity drug," as proposed by researchers at the August 2025 Aging Research and Drug Discovery conference in Copenhagen[17] [18].

Rapamycin and mTOR Inhibition

New clinical trial data continues to emerge for rapamycin, with a low-dose rapamycin trial in myalgic encephalomyelitis (ME) reporting that 72.5% of 40 participants showed improvements in fatigue, post-exertional malaise, and orthostatic intolerance after three months of intermittent dosing[19]. The treatment protocol used 1-4 mg per week—doses substantially lower than those used for immunosuppression—suggesting that rapamycin's anti-aging effects can be achieved without severe immune compromise[19] [20].

Basic Research vs. Clinical Trials: Bridging the Translation Gap

The past week has highlighted both the promise and challenges of translating basic longevity research into clinical applications.

Preclinical Discoveries with Clinical Potential

Several animal model studies have demonstrated dramatic life-extending effects that are now informing human trial design:

- **Alternative RNA Splicing and Longevity**: Research published on November 23, 2025, across 26 mammal species with lifespans ranging from 2.2 to 37 years revealed that changes in how genes are spliced play a key role in determining maximum lifespan[21]. Lifespan-linked splicing was found to be genetically programmed and tightly controlled by RNA-binding proteins, suggesting this represents a "hidden layer of genetic control" that could be therapeutically targeted[21].
- **Mitochondrial Therapy**: Texas A&M researchers announced on November 25, 2025, a method to "recharge aging tissues" by replacing damaged mitochondria in aged human cells with functional mitochondrial "nanoflowers"[22]. The approach restored energy output to youthful levels and significantly enhanced cell vitality, representing a potential breakthrough in combating cellular energy decline.

Human Clinical Trials Advancing to Market

Several therapies have achieved critical regulatory milestones:

- **NAD+ Precursor for Progeroid Disease**: A clinical trial using nicotinamide riboside (NR) in Werner syndrome—a rare genetic disorder causing premature aging—showed that NR safely boosted NAD+ levels while improving cardiovascular health, reducing skin ulcers, and protecting kidney function[23]. This represents the first successful human trial demonstrating that NAD+ precursor supplementation can improve age-related pathologies in humans.
- **Precision Aging Network Data Release**: The University of Arizona-led Precision Aging Network released 300 terabytes of data from four years of research on normal cognitive aging on November 24, 2025[24]. This comprehensive dataset, now publicly available

through the National Institute on Aging's repository, provides unprecedented insights into how the healthy brain ages and represents a major resource for developing healthspan-extending interventions.

Challenges in Translation

The week also highlighted persistent challenges in moving from animal models to human efficacy:

- **Spermidine Supplementation Disappointment**: The SmartAge Trial testing spermidine in older adults with cognitive decline showed no significant cognitive improvements[25]. Moreover, research published in 2023 found that oral spermidine supplementation at 15 mg/day for five days did not increase plasma spermidine levels, raising bioavailability concerns[25].
- **NAD+ Precursor Limitations**: A comprehensive review in *Nature Metabolism* noted that while preclinical studies support NAD+ supplementation as a promising therapeutic strategy, human clinical trials have shown limited efficacy[26]. The published data on NAD+ dynamics in human tissues remains sparse, with extrapolation from rodent studies proving problematic.

Technological Tools: Biomarkers, AI, and Advanced Imaging

AI-Driven Biomarker Development

Photoplethysmography Age as a Vascular Health Marker

Research published on November 18, 2025, in *Nature Communications* introduced AI-PPG age—a deep learning-derived biomarker that estimates biological age from photoplethysmography (PPG) signals obtained from wearable devices[27]. The AI-PPG age gap (the difference between AI-estimated age and chronological age) served as an independent risk factor for major adverse cardiovascular events, diabetes, hypertension, coronary heart disease, heart failure, myocardial infarction, stroke, and all-cause mortality[27].

The approach addresses a critical gap in accessible healthspan monitoring, enabling continuous vascular aging assessment through consumer wearables without requiring invasive procedures or specialized clinical visits.

Comprehensive Aging Biomarker Integration

A review published on November 6, 2025, in *Frontiers in Aging* examined how artificial intelligence and biosensor technologies enhance the measurement and interpretation of key biochemical aging markers including C-reactive protein, IGF-1, interleukin-6, and growth differentiation factor-15[28]. The integration of AI-driven methods including machine learning and deep learning facilitates interpretation of high-dimensional datasets, paving the way for widely accessible, data-informed tools for health monitoring and disease risk assessment[28].

Epigenetic Clocks and Aging Measurement

The 1st World Longevity Summit in Kyotango, Japan (November 13-14, 2025) featured presentations on the latest developments in epigenetic aging clocks[29] [30]. Researchers reported that the rate of epigenetic aging varies across organs, with centenarians showing slower aging in the cerebellum and retina but faster aging in blood and bone. The clocks can detect prenatal development and show full rejuvenation when cells are reprogrammed to induced pluripotent stem cells[30].

Notably, short-term interventions showed mixed results: omega-3 supplementation led to small but statistically significant reductions in biological age in a Swiss clinical trial, while vitamin D and exercise showed no significant impact. Liver methylation age did not significantly decrease in the short term following bariatric surgery[30].

Advanced Imaging for Brain Aging

On November 25, 2025, scientists announced the discovery that more muscle mass and less hidden abdominal fat are linked to a younger biological brain age[31] [32]. This finding, based on advanced brain imaging techniques, provides additional evidence that modifiable lifestyle factors—particularly body composition—have direct impacts on brain aging trajectories.

Ethical and Practical Considerations

Access and Equity Challenges

The democratization of longevity interventions emerged as a critical theme this week. Dr. Richard Siow, Director of Ageing Research, argued that "true longevity is about prevention, mental health, and social policy, not miracle clinics or anti-aging pills"[5]. He emphasized that data and health interventions must be democratized, citing COVID-19 test kit distribution through supermarkets as a model for accessible prevention[5].

The economic implications are substantial. A *Nature* study referenced at the HLTH conference found that extending healthy life expectancy by just one year would yield $38 trillion in economic value over the lifetimes of current populations[33]. Yet access to emerging longevity therapies remains highly unequal, with treatments like Casgevy for sickle cell disease—the first FDA-approved CRISPR therapy—facing significant reimbursement challenges despite demonstrated efficacy[34].

Safety Considerations

Drug Repurposing and Off-Label Use

The week highlighted both opportunities and risks in repurposing existing drugs for longevity applications. Low-dose rapamycin continues to be prescribed off-label by some physicians for Long COVID and ME, despite limited clinical trial data[19] [20]. While preliminary results appear promising, experts emphasize that "this is not a green light for off-label use" and that rapamycin should only be considered within research settings or by experienced clinicians under strict monitoring[20].

Gene Editing Safety

As gene editing advances toward clinical application for age-related diseases, safety remains paramount. The Kentucky team's Alzheimer's gene editing study noted that scientists must ensure treatments don't inadvertently increase risks of other diseases, as the APOE2 variant that protects against Alzheimer's may have other effects on health[14]. "My hope and my belief is that one day—and hopefully it's sooner rather than later—we're at a point where we have tools that can edit DNA efficiently and safely," said lead investigator Dr. Lance Johnson[14].

Cost and Pricing Pressures

Medicare Drug Price Negotiations

On November 25, 2025, the U.S. government announced negotiated prices for 15 of Medicare's costliest drugs, representing a pivotal test of healthcare cost containment efforts[35] [36]. The negotiated prices for drugs including GLP-1 agonists showed substantial reductions: Ozempic and Wegovy prices fell to $245 per month for Medicare beneficiaries, less than half the prices initially proposed[37]. These reductions will enable Medicare to cover obesity drugs for the first time, with estimated savings of $685 million for beneficiaries and $12 billion for the Medicare program[36].

However, pharmaceutical companies have aggressively opposed Medicare negotiations, warning that they may need to scale back drug development initiatives[35]. The tension between access, innovation incentives, and sustainable healthcare financing remains unresolved.

Future Directions: Emerging Trajectories for Human Healthspan

Partial Epigenetic Reprogramming Enters Clinical Trials

Life Biosciences announced on August 26, 2025 (with data presented at the Aging Research and Drug Discovery conference), that its partial epigenetic reprogramming therapy ER-100 will enter human clinical trials in early 2026 for glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION)[38] [39] [40]. This represents a watershed moment: the first clinical application of partial epigenetic reprogramming—using three Yamanaka factors (Oct4, Sox2, and Klf4) to reset cellular age without inducing full dedifferentiation[41].

The company also presented preclinical data on ER-300 for metabolic dysfunction-associated steatohepatitis (MASH), demonstrating improvements in multiple liver health biomarkers including ALT, AST, total cholesterol, and NAFLD scores[38]. "Since we started talking about our work in optic neuropathies, everyone asks the same questions: Is this just the beginning? What's next? Where are you going?" said Chief Scientific Officer Dr. Sharon Rosenzweig-Lipson. "So we decided it was time to share more information about what we're doing"[39].

Thymus Regeneration for Immune System Restoration

The TRIIM-X (Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension) trial continues recruiting participants for an expanded evaluation of personalized thymus regeneration protocols[42] [43]. The original TRIIM trial (2015-2017) demonstrated unprecedented reversal of epigenetic aging, with participants reducing their biological age by over two years after one year of treatment using a combination of recombinant human growth hormone, metformin, and DHEA[42].

Complementing this work, multiple companies including Tolerance Bio ($17.2 million seed financing), Thymmune, Vidaregen, and Thymox are developing diverse approaches to preserve, regenerate, and manipulate the thymus[44]. Tolerance Bio is developing artificial thymuses from stem cells and drugs to delay thymic involution, with the goal of combating immune diseases while extending healthy lifespan[44].

Microbiome-Longevity Connections

Research published on November 20, 2025, examining gut microbiota in 82 captive giant pandas across juvenile, adult, and geriatric cohorts revealed age-dependent succession patterns and identified specific bacterial taxa associated with exceptional longevity[45]. Long-lived pandas exhibited elevated abundance of *Akkermansia muciniphila*, *Bifidobacterium longum*, *Lactobacillus intestinalis*, and *Ruminococcus gnavus*[45].

On November 10, 2025, Janelia researchers demonstrated that gut bacteria can be induced to overproduce longevity-promoting compounds like colanic acid through exposure to low doses of antibiotics that don't get absorbed systemically[46] [47]. This approach—manipulating the microbiome to produce beneficial metabolites rather than directly administering them—represents a novel drug development strategy with potential applications across species.

Multi-Modal Combination Therapies

Evidence is mounting that the most effective longevity interventions will combine multiple mechanisms. Research published in *Nature Aging* in June 2025 showed that combining rapamycin with trametinib—targeting interconnected mTOR and MEK pathways—produced additive lifespan extensions of 29% and 27% in female and male mice, respectively[48]. This exceeds the benefits of either drug alone and supports a paradigm shift toward multi-pathway interventions.

Similarly, the XPRIZE Healthspan competition—a 7-year, $101 million global challenge—is incentivizing teams to develop therapeutics that restore muscle, cognitive, and immune function by a minimum of 10 years, with an ambitious goal of 20 years, specifically through multi-modal approaches[49].

Regulatory Pathways for Personalized Therapies

On November 24, 2025, the FDA outlined a "plausible mechanism" approval pathway for personalized therapies, establishing a precedent that could accelerate development of individualized gene editing and cell therapy interventions[50]. The pathway requires confirmatory evidence of successful target modulation and durable clinical improvements, but explicitly allows evidence from animal models, nonanimal models, or clinical biopsies—and may accept evidence from a subset of patients or even the first dosed subject[50].

This regulatory flexibility enabled the rapid approval of a personalized CRISPR therapy for an infant with CPS1 deficiency, developed and delivered in just six months[34]. Such precedents suggest that highly personalized longevity interventions may reach patients far more quickly than traditional drug development timelines would allow.

Conclusion: A Pivotal Week for Functional Life Extension

The discoveries of November 18-25, 2025, represent more than incremental progress—they signal a fundamental maturation of longevity science. For the first time, multiple interventions targeting core aging mechanisms are simultaneously advancing through human clinical trials, achieving regulatory approvals, and demonstrating measurable improvements in healthspan markers.

Blood stem cell rejuvenation through RhoA inhibition[1] [2] [4], immune system restoration via urolithin A[13] [12], gene editing for Alzheimer's prevention[14], and GLP-1-mediated multi-organ rejuvenation[16] collectively demonstrate that aging is not an immutable biological destiny but a malleable process amenable to therapeutic intervention.

Critical challenges remain. Translation from animal models to human efficacy is inconsistent[26] [25]. Access and equity gaps threaten to create a longevity divide where only affluent populations benefit from life-extending therapies[5]. Regulatory frameworks continue evolving to accommodate personalized and platform therapies[50]. The long-term safety of interventions targeting fundamental aging mechanisms requires continued vigilance[14] [20].

Yet the trajectory is unmistakable. As Dr. Ghaffari observed regarding blood stem cell rejuvenation: "Our findings reveal that aging in blood stem cells is not an irreversible fate. Old blood stem cells have the capacity to revert to a youthful state; they can bounce back"[2]. This principle—that aging processes can be reversed rather than merely slowed—increasingly appears to apply across organ systems and biological scales.

The question is no longer whether functional life extension is possible, but how rapidly effective interventions can be developed, validated, and equitably distributed to populations facing the burdens of age-related disease. The discoveries of the past week suggest that timeline may be shorter than previously imagined.

⁂

1. https://www.drugtargetreview.com/news/190920/rhosin-shown-to-reverse-blood-stem-cell-ageing/
2. https://medicalxpress.com/news/2025-11-scientists-reverse-aging-blood-stem.html

3. https://www.mountsinai.org/about/newsroom/2025/mount-sinai-scientists-reverse-aging-in-blood-stem-cells-by-targeting-lysosomal-dysfunction
4. https://www.nature.com/articles/s43587-025-01014-w
5. https://www.worldhealthexpo.com/insights/healthcare-management/healthcare-systems-under-pressure-as-life-expectancy-goals-intensify
6. https://www.livescience.com/health/diabetes/slaying-zombie-cells-in-blood-vessels-could-be-key-to-treating-diabetes-early-study-finds
7. https://medicalxpress.com/news/2025-11-aged-blood-vessel-cells-metabolic.html
8. https://www.ophthalmologytimes.com/view/aao-2025-takeaways-the-next-frontier-in-retinal-therapeutics-arrives
9. https://www.eurekalert.org/news-releases/1106849
10. https://medicalxpress.com/news/2025-11-boosting-telomerase-lung-cell-aging.html
11. https://www.ajmc.com/view/telomere-dysfunction-may-be-therapeutic-target-in-pf
12. https://www.popularmechanics.com/science/a69492467/compound-de-age-immune-systems/
13. https://www.biospace.com/press-releases/timeline-continues-to-build-the-most-clinically-researched-longevity-products-targeting-immune-brain-and-muscle-aging
14. https://linknky.com/news/2025/11/24/kentucky-gene-editing-alzheimers-research-mice-study/
15. https://crisprmedicinenews.com/news/cmn-weekly-21-november-2025-your-weekly-crispr-medicine-news/
16. https://www.news-medical.net/news/20251123/Study-finds-GLP-1-drugs-improve-strength-and-reverse-aging-biology-in-mice.aspx
17. https://fortune.com/2025/11/21/glp-drugs-anti-obesity-drugs-longevity/
18. https://www.nature.com/articles/s41587-025-02932-1
19. https://thesicktimes.org/2025/07/29/clinical-trials-are-testing-cancer-drug-rapamycin-for-long-covid-and-me/
20. https://danilobuonsenso.substack.com/p/low-dose-rapamycin-for-mecfs-and
21. https://news.ucr.edu/articles/2025/11/24/new-clues-why-some-animals-live-longer
22. https://www.newsweek.com/breakthrough-toward-recharging-aging-tissues-mitochondria-nanoflowers-11106487
23. https://www.sciencedaily.com/releases/2025/06/250609020625.htm
24. https://news.arizona.edu/news/precision-aging-network-data-release-opens-new-pathways-healthy-aging-research
25. https://healthpath.com/gut-health/spermadine/
26. https://pubmed.ncbi.nlm.nih.gov/41083806/
27. https://www.nature.com/articles/s43856-025-01188-9
28. https://www.frontiersin.org/journals/aging/articles/10.3389/fragi.2025.1703698/full
29. https://www.nature.com/articles/s41514-025-00279-0
30. https://pmc.ncbi.nlm.nih.gov/articles/PMC12627732/
31. https://www.sciencedaily.com/releases/2025/11/251125112506.htm
32. http://www.sciencedaily.com/releases/2025/11/251125112506.htm

33. https://community.hlth.com/insights/articles/the-age-of-longevity-and-the-healthspan-economy-2025-11-25
34. https://innovativegenomics.org/news/crispr-clinical-trials-2025/
35. https://www.reuters.com/business/healthcare-pharmaceuticals/us-negotiated-medicare-prices-15-more-drugs-test-cost-savings-promise-2025-11-25/
36. https://www.politico.com/news/2025/11/25/trumps-cms-touts-12b-savings-from-medicare-drug-price-negotiations-00669231
37. https://www.whitehouse.gov/fact-sheets/2025/11/fact-sheet-president-donald-j-trump-announces-major-developments-in-bringing-most-favored-nation-pricing-to-american-patients/
38. https://www.clinicaltrialvanguard.com/news/life-biosciences-unveils-new-data-on-epigenetic-reprogramming-at-ardd-2025/
39. https://longevity.technology/news/life-bio-epigenetic-rejuvenation-transcends-organs/
40. https://www.bioworld.com/articles/723608-ardd-2025-hitting-rewind-not-reset-for-in-vivo-rejuvenation
41. https://www.nmn.com/news/life-biosciences-co-founded-by-harvards-david-sinclair-reveals-promising-data-on-age-reversing-drug-candidates
42. https://www.linkedin.com/pulse/thymus-regeneration-triim-x-trial-currently-margaretta-colangelo-1c
43. https://www.clinicaltrials.gov/study/NCT04375657
44. https://longevity.technology/investment/tolerance-bio-launches-to-boost-human-healthspan-via-the-thymus/
45. https://academic.oup.com/cz/advance-article/doi/10.1093/cz/zoaf074/8339601
46. https://www.janelia.org/news/turning-the-gut-microbiome-into-a-longevity-factory
47. https://scitechdaily.com/scientists-discover-how-to-turn-gut-microbiome-into-a-longevity-factory/
48. https://www.nad.com/news/latest-research-two-fda-approved-drugs-additively-extend-lifespan
49. https://www.xprize.org/competitions/healthspan
50. https://www.ropesgray.com/en/insights/alerts/2025/11/fda-outlines-plausible-mechanism-approval-pathway-for-personalized-therapies-but-significant
51. https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/expiration-dating-extension
52. https://www.fpwr.org/fpwr-funded-projects/investigation-of-rapamycin-as-a-therapeutic-option-in-a-mouse-model-of-schaaf-yang-syndrome-sys
53. https://www.instagram.com/p/DRC2PqbkiMy/
54. https://vetmedbiosci.colostate.edu/vth/clinical-trials/trac-study/
55. https://www.mdiha.com/blog/newest-trends-in-stem-cell-therapy-for-age-related-conditions
56. https://parentsguidecordblood.org/en/news/cord-blood-and-anti-aging
57. https://www.sciencedaily.com/releases/2025/11/251121090736.htm
58. https://www.science.org/content/article/young-blood-renews-old-mice
59. https://stemcell-conference.westlake.edu.cn
60. https://www.simonsfoundation.org/2022/06/06/exploring-how-young-blood-helps-reverse-signs-of-aging-in-old-brains/
61. https://www.biospace.com/press-releases/maia-biotechnology-highlights-ongoing-momentum-of-ateganosine-clinical-program-at-sitc-2025

62. https://cell-symposia.com/stem-cells-2025/
63. https://academic.oup.com/biomedgerontology/article/79/5/glae071/7618060
64. https://ir.maiabiotech.com/news-events/press-releases/detail/157/maia-biotechnology-ceo-presents-telomere-targeting-efficacy
65. https://natureconferences.streamgo.live/stem-cells-across-the-lifespan-embryogenesis-aging-therapy
66. https://www.nmn.com/news/new-harvard-study-anti-aging-senolytics-are-safe-for-seniors-with-memory-loss
67. https://www.nad.com/news/anti-aging-breakthrough-dr-david-sinclair-predicts-age-reversing-pill-by-2035
68. https://www.ku.ac.ae/khalifa-university-inaugurates-healthy-longevity-symposium-2025-with-global-experts-exploring-biomedical-research-and-science-and-policy-of-wellbeing
69. https://longevitygl.org/agenda-2024/
70. https://ezra.com/en-gb/blog/senolytic-supplements-slow-ageing
71. https://seedfunding.stanford.edu/opportunities/stanford-medicines-longevity-and-healthy-aging-pilot-grants-2025-2026
72. https://www.drbaxter.com/blog/top-stories-in-longevity-2025/
73. https://natureconferences.streamgo.live/nature-forum-aging
74. https://www.lifeextension.com/magazine/2025/11/senolytics-brain-aging
75. https://www.med.wisc.edu/news/new-research-center-on-aging/
76. https://www.sciencedirect.com/science/article/abs/pii/S1550413125004437?via%3Dihub
77. https://www.gsa2025.org
78. https://www.insights.onegiantleap.com/blogs/genetic-engineering-and-the-quest-for-longevity/
79. https://clinicaltrials.gov/study/NCT06882096
80. https://www.sciencedaily.com/releases/2025/11/251105050720.htm
81. https://www.asgct.org/events-meetings/breakthroughs-in-targeted-in-vivo-gene-editing
82. https://newsroom.heart.org/news/first-in-human-trial-of-crispr-gene-editing-therapy-safely-lowered-cholesterol-triglycerides
83. https://www.psychiatrist.com/news/nad-revives-memory-in-alzheimers-models/
84. https://www.nytimes.com/2025/11/19/health/gene-editing-rare-diseases.html
85. https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2025/11/23/20/14/CRISPR-Cas9
86. https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00567-X/fulltext
87. https://www.globalwellnesssummit.com/press/press-releases/longevity-takes-the-spotlight-global-wellness-summit-announces-first-wave-of-trailblazing-speakers-for-19th-annual-gathering/
88. https://www.tctmd.com/news/crispr-cas9-gene-editing-therapy-shows-early-promise-dyslipidemia
89. https://www.nad.com/news/nad-booster-nicotinamide-and-vitamin-b6-activate-muscle-stem-cells-to-counter-muscle-shrinkage-new-studies-show
90. https://www.nature.com/articles/d41586-025-03524-4
91. https://singularityhub.com/2025/11/18/scientists-race-to-deliver-custom-gene-therapies-for-incurable-diseases-in-weeks-not-years/
92. https://coursesandconferences.wellcomeconnectingscience.org/event/mitochondrial-medicine-therapeutic-development-20251110/

93. https://finance.yahoo.com/news/mitochondrial-myopathies-market-register-stunning-223100269.html
94. https://orsobio.com/events/orsobio-to-present-clinical-and-preclinical-data-on-mitochondrial-protonophore-portfolio-for-obesity-at-obesityweek-2025/
95. https://www.ssiem.org/24-events/342-10-12-november-2025.html
96. https://www.drugtargetreview.com/article/190428/ai-and-the-future-of-biomarker-analysis-in-early-rd/
97. https://ern-euro-nmd.eu/educational-news/9th-meeting-mitochondrial-medicine-therapeutic-development-10-12-november-2025/
98. https://www.prnewswire.com/news-releases/ai-detects-first-imaging-biomarker-of-chronic-stress-302623383.html
99. https://pubmed.ncbi.nlm.nih.gov/41258574/
100. https://umdf.org/events/month/2025-11/
101. https://www.agingconsortium.org/conference-home
102. https://www.prnewswire.com/news-releases/made-scientific-and-cellergy-therapeutics-announce-manufacturing-partnership-to-advance-first-in-human-mitochondrial-therapy-302624670.html
103. https://pmc.ncbi.nlm.nih.gov/articles/PMC12635586/
104. https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2021.717343/full
105. https://www.nature.com/articles/s43856-025-00904-9
106. https://pubmed.ncbi.nlm.nih.gov/40553215/
107. https://loyal.com/posts/loy-002-receives-rxe-from-the-fda
108. https://www.facebook.com/santanaheartsd/posts/calorie-restriction-mimetics-against-aging-and-inflammation-2025review-molecule/835054702622903/
109. https://www.clinicaltrials.gov/study/NCT06257420
110. https://journals.physiology.org/doi/prev/20171106-aop/abs/10.1152/physiolgenomics.00069.2005?doi=10.1152%2Fphysiolgenomics.00069.2005
111. https://www.nad.com/news/longevity-drug-rapamycin-improves-the-heart-of-older-adults-new-study-shows
112. https://academic.oup.com/cardiovascres/article-abstract/117/6/1434/5938079
113. https://finance.yahoo.com/news/psyence-biomed-announces-groundbreaking-psilocybin-120000971.html
114. https://pmc.ncbi.nlm.nih.gov/articles/PMC12538759/